CymaBay Therapeutics Presents New Findings that Seladelpar Treatment of PBC Patients for Two Years Predicts Improved Transplant-Free Survival

Source :: GlobeNewswire. May 23, 2022
Publication Year :: 2022
Abstract: NEWARK, May 23, 2022 (GLOBE NEWSWIRE via COMTEX) -- EQNX::TICKER_START (NASDAQ:CBAY), EQNX::TICKER_END CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for [...]

Subjects :: Medical research
Medicine, Experimental
Chronic diseases -- Patient outcomes
Liver
College teachers
Gastrointestinal diseases -- Patient outcomes
Evidence-based medicine
Banking, finance and accounting industries
Business

Tools